FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter...
Under the terms for the line of credit, IGC can draw up to $1 million within a 30-day period. The interest rate for a draw is 1% plus the rate paid on cert...
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today...
The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Nai...
Microba and Sonic Healthcare signed a commercial agreement to sell Microba's advanced infectious disease testing technology MetaPanel™ in Australia...
-Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early le...
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon...
The strategic stockpile has been established to enable rapid deployment to EU member states and other countries participating in the EU Civil Protection Me...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain's field pot...
This study, conducted by experts from Aquarius Population Health Limited in London and the University of Manchester, presents valuable insights into the co...
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life fo...
Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approved Across all clinical ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab...
© 2025 Biopharma Boardroom. All Rights Reserved.
